WEBULL
News
GPCR
67.38
-1.40%
-0.96
My Market Outlook For 2026: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
Seeking Alpha · 5h ago
Weekly Report: what happened at GPCR last week (1222-1226)?
Weekly Report · 12h ago
NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?
NASDAQ · 5d ago
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
NASDAQ · 6d ago
Regencell Bioscience is the top performing pharma stock YTD
Seeking Alpha · 6d ago
Weekly Report: what happened at GPCR last week (1215-1219)?
Weekly Report · 12/22 09:09
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga · 12/21 14:30
Structure Therapeutics Inc. - Depositary Receipt (GPCR) Price Target Increased by 21.89% to 94.31
NASDAQ · 12/21 10:48
Structure Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/19 15:33
Structure Therapeutics Price Target Raised to $90.00/Share From $60.00 by HC Wainwright & Co.
Dow Jones · 12/19 15:33
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Raises Price Target to $90
Benzinga · 12/19 15:22
Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright
TipRanks · 12/19 13:45
STRUCTURE THERAPEUTICS INC. <GPCR.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $90 FROM $60
Reuters · 12/19 13:45
BUZZ-Obesity pill maker Structure gains after Lilly's pill shows promising trial data
Reuters · 12/18 15:31
Structure Therapeutics Initiates First-In-Human Phase 1 Clinical Study Of ACCG-2671, Lead Oral Small Molecule Amylin Receptor Agonist For Obesity Treatment
Benzinga · 12/17 13:38
Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671
TipRanks · 12/17 13:35
Structure Therapeutics Launches Phase 1 Trial of Oral Amylin Agonist ACCG-2671 for Obesity
Reuters · 12/17 13:30
STRUCTURE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY OF ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 FOR THE TREATMENT OF OBESITY
Reuters · 12/17 13:30
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
NASDAQ · 12/15 15:32
Weekly Report: what happened at GPCR last week (1208-1212)?
Weekly Report · 12/15 09:10
More
Webull provides a variety of real-time GPCR stock news. You can receive the latest news about Structure Therapeutics Inc ADR through multiple platforms. This information may help you make smarter investment decisions.
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.